Conclusions & Recommendations
25.2.3 - Country gaps
Conclusion/Recommendation:
TEC recommends that ITI work with ICTC to develop a list of gaps:
- suspected endemic districts needing mapping
- funding gaps (R1s + any districts TF ≥5% but without MDA)
- TT support gaps – in collaboration with BMGF, USAID, Accelerate, ESPEN
Action:
ITI is working with ICTC on identifying these gaps as part of the revised ICTC Strategic Plan 2021-2030.
TEC 25
2021
recommendations for ITI management, ICTC, funding, suspected endemic
25.3.1 - Next steps for Zithromax® decision-making in districts with persistent (Category 1) & recrudescent (Category 2) trachoma
Conclusion/Recommendation:
ITI to create a line listing of all Category 1 & 2 districts (including populations) to:
- Quantify potential additional Zithromax® need for 2022 and discuss projected production forecast changes with Pfizer
- Flag districts on 2023 Zithromax® Applications
- Determine which countries need to be approached urgently for additional discussion/support from TEC & ITI for 2022 and 2023 treatments
- Identify which programs and partners should be included in TEC 26 meeting
Action:
ITI shared the new TEC guidance on modified strategies in persistent and recrudescent districts with all trachoma endemic countries and implementing partners. ITI has been working closely with national programs and other partners to prepare for the TEC 26 meeting, where requests for modified strategies in 2022 will be considered. Each country submitting a revised 2022 Zithromax® Application has been invited to participate in TEC 26 to present their plans for a modified strategy. ITI is also working with national programs on preparing their 2023 Zithromax® requests, which will allow a refinement of the 2023 production forecast.
TEC 25
2021
persistence, recommendations for ITI management, alternative treatment strategies, Zithromax® donation criteria
25.3.2 - Next steps for Zithromax® decision-making in districts with persistent (Category 1) & recrudescent (Category 2) trachoma
Conclusion/Recommendation:
ITI to draft a letter for TEC review to communicate changes to the national programs and partners about Zithromax® decision-making in Category 1 & 2 districts based on recommendations from the WHO Informal Consultation, AND information about catch-up rounds in other districts.
Action:
A letter was drafted and shared in January 2022. (https://bit.ly/ITI-TEC-Persistence-Recrudescence)
TEC 25
2021
persistence, alternative treatment strategies, recommendations for ITI management, Zithromax® donation criteria
25.3.3 - Next steps for Zithromax® decision-making in districts with persistent (Category 1) & recrudescent (Category 2) trachoma
Conclusion/Recommendation:
TEC recommends that ITI and the TEC liaisons work closely with national programs, their implementing partners, and donors in each country with Category 1 & 2 districts to:
- help interpret the new guidance, and
-develop a package of information supporting TEC’s consideration of Applications at TEC 26 (2022 treatments) & TEC 27 (2023 treatments)
Action:
A letter was drafted and shared in January 2022. (https://bit.ly/ITI-TEC-Persistence-Recrudescence)
TEC 25
2021
persistence, alternative treatment strategies, Zithromax® donation criteria, recommendations for ITI management
25.3.4 - Next steps for Zithromax® decision-making in districts with persistent (Category 1) & recrudescent (Category 2) trachoma
Conclusion/Recommendation:
TEC recommends that ITI Management track Category 1 & 2 requests, TEC allocation decisions in those districts, and lessons learned as this new TEC guidance is implemented
Action:
This is ongoing.
TEC 25
2021
alternative treatment strategies, persistence, recommendations for ITI management, Zithromax® donation criteria
25.4.1 - Future TEC Meetings
Conclusion/Recommendation:
TEC 26: March 29-31, 2022 in London, UK – This meeting will focus on reconsidering TEC decisions for 2022 in Category 1 & 2 districts. Participants will include TEC, implementing partners and donors and program managers in countries with 2022 Applications in Category 1 & 2 districts that would like to propose a different strategy
Action:
No action required
TEC 25
2021
TEC meeting management
25.4.2 - Future TEC Meetings
Conclusion/Recommendation:
TEC 27: June 13 – 16, 2022 in Atlanta, GA, USA – an extra day has been added to allow more discussion time for Category 1 & 2 district decision-making.
Action:
No action required
TEC 25
2021
TEC meeting management
25.4.3 - Future TEC Meetings
Conclusion/Recommendation:
TEC 28: November 15 – 17, 2022 in Cape Town, South Africa – suggested agenda items include:
- Reviewing data from co-administration trials
- Updates from REACH trials (particularly Côte d’Ivoire, ideally including participation by the national program coordinator)
- A focus on Antimicrobial Resistance (AMR) monitoring and how it may affect communication between TEC members and partners
Action:
No action required
TEC 25
2021
TEC meeting management
24.1.1 - General Recommendations
Conclusion/Recommendation:
Include district-level data on infection, where available, to provide a more complete picture of trachoma in these areas (using publicly-available data and/or with permission from the MOH/researchers)
Action:
A new column to track this has been added to the TEMFs and publicly-available data is included in the Notes column on the Zithromax® Applications
TEC 24
2021
alternative indicators (Ct, serology), TEC meeting management
24.1.2 - General Recommendations
Conclusion/Recommendation:
include Zithromax® requests for research as rows on the applications (e.g., REACH; Stronger SAFE; KETFO)
Action:
A research request form has been added to the surgery request form to track these requests with greater detail
TEC 24
2021
TEC meeting management, research